Targets › ADRA1D
39 programs from 37 companies in 61 trials: 25 Phase 4, 14 Phase 2, 12 Phase 3, 10 Phase 1; Cardiovascular, Other, Neurology; next expected readout Dec 2026.
Alpha-1 adrenergic receptors are G protein-coupled receptors for catecholamines that signal through the G(q) family of G proteins, including G(q) and G(11). Upon activation, they stimulate the phosphatidylinositol-calcium second messenger pathway, leading to calcium release from intracellular stores and activation of protein kinase C. ADRA1D binds the catecholamine ligands norepinephrine and epinephrine. (UniProt, P25100)
Open in Phaseline: the race on ADRA1D, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Chicago | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Shock | Dec 2026 |
| King's College Hospital NHS Trust | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Cirrhosis, Liver | Dec 2026 |
| Sohag University | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Patients Undergoing Orthopedic Hip Surgery Under Spinal Anesthesia | Mar 2027 |
| University of Alberta | Midodrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Vasoplegia | Mar 2027 |
| Hospital Sirio-Libanes | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Cancer | May 2027 |
| James J. Peters Veterans Affairs Medical Center | Midodrine Hydrochloride Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Hypotension | Jun 2027 |
| Seoul National University Hospital | Phenoxybenzamine Adrenergic receptor alpha antagonist | ADRA1A, ADRA2A, ADRA2C, ADRA1D, ADRA1B | Phase 4 | Pheochromocytoma | Aug 2027 |
| University of Alberta | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Vasoconstriction | Dec 2027 |
| Post Graduate Institute of Medical Education and Research, Chandigarh | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Cirrhotic Cardiomyopathy | Jan 2029 |
| Taipei Veterans General Hospital, Taiwan | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Hepatocellular Carcinoma (HCC); Cirrhosis | Oct 2030 |
| University of Rochester | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Heart Failure With Reduced Ejection Fraction (HFrEF) | Jun 2031 |
| Chinese University of Hong Kong | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Portal Hypertension | Jul 2031 |
| Bispebjerg Hospital | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Acute Myocardial Infarction | Dec 2035 |
| Dalian Municipal Central Hospital | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Hypotension Drug-Induced | – |
| Rawalpindi Medical College | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Phenylephrine | – |
| Hassan II University | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Cesarean Section Complications | – |
| VA Office of Research and Development | Prazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 3 | Posttraumatic Stress Disorder | Dec 2026 |
| Bir Hospital | Tamsulosin Hydrochloride Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 3 | Ureteral Stent-Related Symptom | Dec 2026 |
| Penang Hospital, Malaysia | Terazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 3 | Stent Related Symptoms | May 2027 |
| CHU de Quebec-Universite Laval | Tamsulosin hydrochloride Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 3 | Urinary Retention | Jul 2027 |
| Opus Genetics | Phentolamine Ophthalmic Solution 0.75% Non-selective alpha-1 and alpha-2 adrenergic antagonist | ADRA1A, ADRA1B, ADRA1D, ADRA2A | Phase 3 | Vision Loss Night; Insulin Resistance | Aug 2027 |
| University College, London | Terazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 3 | Parkinsons Disease (PD) | May 2031 |
| SWOG Cancer Research Network | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 3 | Cardiotoxicity | Jun 2031 |
| Ain Shams University | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 3 | Cardiotoxicity | – |
| Santen SAS | Oxymetazoline (STN1013800) Adrenergic receptor alpha agonist | ADRA1A, ADRA2A, ADRA2C, ADRA1D, ADRA1B | Phase 3 | Acquired Blepharophimosis; Sleep Apnea; Perioperative Respiratory Adverse Events; Nasal Obstruction | – |
| Brown University | Doxazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 2 | Alcohol Use Disorder (AUD) | Dec 2026 |
| University of Wisconsin, Madison | Prazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 2 | Magnetic Resonance Imaging | May 2027 |
| University of Aarhus | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 2 | Hypotension | Dec 2027 |
| Ottawa Heart Institute Research Corporation | Midodrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 2 | Heart Failure With Reduced Ejection Fraction | Jun 2028 |
| Sherief Abd-Elsalam | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 2 | Esophageal Varices | Dec 2030 |
| Michele Tagliati, MD | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 2 | REM Sleep Behavior Disorder | – |
| Cedars-Sinai Medical Center | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 2 | REM Sleep Behavior Disorder | – |
| Cedars-Sinai Medical Center | Terazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 2 | REM Sleep Behavior Disorder; Symptomatic Parkinson Disease | – |
| Kingston Health Sciences Centre | phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 2 | Shock | – |
| University of Manitoba | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 1 | Blood Loss, Surgical | Jun 2028 |
| Montefiore Medical Center | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 1 | Mitral Regurgitation | – |
| Berlin-Chemie AG Menarini Group | Tamsulosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 1 | Healthy Volunteers; Healthy Adult Males Volunteers; Healthy Volunteer Male Subjects; Nephrolithiasis … | – |
| University of Iowa | Terazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 1 | Healthy | – |
| Mansoura University | carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 1 | TBI Traumatic Brain Injury | – |
REM Sleep Behavior Disorder (3) Stent Related Symptoms (2) Urinary Retention (2) Hypotension (2) Cardiotoxicity (2) Phenylephrine (2) Magnetic Resonance Imaging (2) Shock (2) Parkinsons Disease (PD) (1) Symptomatic Parkinson Disease (1) Pheochromocytoma (1) Ureteral Stent-Related Symptom (1)
small molecule (38)
Cedars-Sinai Medical Center (2) University of Alberta (2) University College, London (1) Seoul National University Hospital (1) Bir Hospital (1) Santen SAS (1) Berlin-Chemie AG Menarini Group (1) Taipei Veterans General Hospital, Taiwan (1) Brown University (1) James J. Peters Veterans Affairs Medical Center (1) University of Rochester (1) Chinese University of Hong Kong (1) Ain Shams University (1) University of Iowa (1) King's College Hospital NHS Trust (1) SWOG Cancer Research Network (1) Post Graduate Institute of Medical Education and Research, Chandigarh (1) Ottawa Heart Institute Research Corporation (1) Dalian Municipal Central Hospital (1) Sohag University (1)
ADRA1A (39) ADRA1B (26) ADRB1 (13) ADRB2 (13) ADRB3 (13) ADRA2A (3) ADRA2C (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.